Alcon Announces Amended Merger Agreement With STAAR Surgical, Raises Bid

GENEVA—Alcon (SIX/NYSE: ALC), a global leader in eyecare, announced that it has entered into an amended merger agreement for the acquisition of STAAR Surgical Company (NASDAQ: STAA), the developer of phakic intraocular lenses with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction. Under the terms of the amended agreement, Alcon will purchase all outstanding shares of STAAR, marking a transaction with a total equity value of approximately $1.6 billion, the announcement stated. This figure represents a 74 percent premium to STAAR’s 90-day volume weighted average price (VWAP) and a 66 percent premium to the closing price of STAAR common stock on August 4, 2025. It also marks an increase in acquisition price compared with when the deal was first announced in August, as well as reductions in payments to executives, the company stated.